stoxline Quote Chart Rank Option Currency Glossary
  
AstraZeneca PLC (AZN)
70.08  -0.24 (-0.34%)    07-16 16:00
Open: 69.96
High: 70.695
Volume: 3,184,809
  
Pre. Close: 70.32
Low: 69.86
Market Cap: 434,560(M)
Technical analysis
2025-07-17 8:43:40 AM
Short term     
Mid term     
Targets 6-month :  85.26 1-year :  88.04
Resists First :  73 Second :  75.37
Pivot price 70.47
Supports First :  69.15 Second :  57.53
MAs MA(5) :  71.01 MA(20) :  70.49
MA(100) :  71.62 MA(250) :  73.01
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  47.2 D(3) :  59.2
RSI RSI(14): 45.9
52-week High :  87.68 Low :  61.24
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AZN ] has closed above bottom band by 37.4%. Bollinger Bands are 53.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 70.78 - 71.22 71.22 - 71.53
Low: 68.8 - 69.36 69.36 - 69.75
Close: 69.35 - 70.16 70.16 - 70.74
Company Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Headline News

Wed, 16 Jul 2025
AstraZeneca’s Promising Phase II Study on AZD7798 for Crohn’s Disease - TipRanks

Wed, 16 Jul 2025
AstraZeneca’s Promising Update on AZD2936 for Advanced NSCLC - TipRanks

Wed, 16 Jul 2025
AstraZeneca’s New Study Targets COPD Burden in Egypt: What Investors Need to Know - The Globe and Mail

Wed, 16 Jul 2025
AstraZeneca’s INTERSTELLAR Study: Real-World Insights into Anifrolumab for SLE - The Globe and Mail

Tue, 15 Jul 2025
AstraZeneca PLC (AZN) Secures EU Approval for Imfinzi - Yahoo Finance

Mon, 14 Jul 2025
AstraZeneca’s Baxdrostat hits all Phase III endpoints, eyes 2025 filing | AZN SEC Filing - Form 6-K - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Shares Out 3,100 (M)
Shares Float 1,540 (M)
Held by Insiders 0 (%)
Held by Institutions 17 (%)
Shares Short 7,450 (K)
Shares Short P.Month 7,340 (K)
Stock Financials
EPS 2.48
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 26.47
Profit Margin 14.1 %
Operating Margin 27.9 %
Return on Assets (ttm) 8.1 %
Return on Equity (ttm) 19.7 %
Qtrly Rev. Growth 7.1 %
Gross Profit (p.s.) 14.62
Sales Per Share 17.73
EBITDA (p.s.) 5.89
Qtrly Earnings Growth 33.5 %
Operating Cash Flow 13,090 (M)
Levered Free Cash Flow 9,350 (M)
Stock Valuations
PE Ratio 28.25
PEG Ratio 0
Price to Book value 2.64
Price to Sales 3.95
Price to Cash Flow 16.59
Stock Dividends
Dividend 1.04
Forward Dividend 0
Dividend Yield 1.4%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android